769916-07-6 Usage
Uses
Used in Pharmaceutical Industry:
6-bromoquinazoline-4-carboxylic acid is used as a precursor in the synthesis of new drug compounds due to its unique chemical structure and potential pharmacological properties. Its presence in the quinazoline class of compounds suggests it may have therapeutic applications, particularly in the development of treatments for various diseases.
Used in Organic Synthesis:
In the field of organic synthesis, 6-bromoquinazoline-4-carboxylic acid is used as a building block for creating a variety of quinazoline-based compounds. Its bromine atom allows for versatile chemical reactions, facilitating the formation of diverse derivatives that can be further explored for their potential applications in various chemical and pharmaceutical processes.
Used in Chemical Research:
6-bromoquinazoline-4-carboxylic acid is utilized in chemical research to study its reactivity and the potential of its bromine atom in facilitating various chemical reactions. This research can lead to a better understanding of the compound's properties and its use in developing new methodologies and applications in chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 769916-07-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,6,9,9,1 and 6 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 769916-07:
(8*7)+(7*6)+(6*9)+(5*9)+(4*1)+(3*6)+(2*0)+(1*7)=226
226 % 10 = 6
So 769916-07-6 is a valid CAS Registry Number.
InChI:InChI=1/C9H5BrN2O2/c10-5-1-2-7-6(3-5)8(9(13)14)12-4-11-7/h1-4H,(H,13,14)
769916-07-6Relevant academic research and scientific papers
SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT
-
Paragraph 00111; 00113, (2020/03/15)
This disclosure relates to low molecular weight substituted imidazoles that inhibit the TGF-b signaling pathway. More specifically, this disclosure relates to methods of using said imidazoles for the treatment of diseases related to the TGF-b signaling pathways including, but not limited to, atherosclerosis, Marfan syndrome, Loeys-Dietz syndrome, obesity, diabetes, multiple sclerosis, keratoconus, idiopathic pulmonary fibrosis, Alzheimer's Disease, chronic kidney disease, and scleroderma.
